NASDAQ:CDXS Codexis Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.81 +0.13 (+1.11 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$11.67Now: $11.81▼$12.0150-Day Range$11.41MA: $12.81▼$13.8252-Week Range$8.43Now: $11.81▼$18.87Volume208,710 shsAverage Volume382,597 shsMarket Capitalization$698.29 millionP/E RatioN/ADividend YieldN/ABeta0.8 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCodexis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.50, Codexis has a forecasted upside of 56.6% from its current price of $11.81.Amount of Analyst CoverageCodexis has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesCodexis has received 315 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCodexis has received 328 “underperform” votes. (Add your “underperform” vote.)Community SentimentCodexis has received 51.01% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Codexis and other stocks. Vote “Outperform” if you believe CDXS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CDXS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCodexis does not currently pay a dividend.Dividend GrowthCodexis does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Codexis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,975.00 in company stock.Percentage Held by InsidersOnly 10.70% of the stock of Codexis is held by insiders.Percentage Held by Institutions91.46% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Codexis are expected to grow in the coming year, from ($0.48) to ($0.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Codexis is -49.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Codexis is -49.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCodexis has a P/B Ratio of 6.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.51 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Industrial organic chemicals Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CDXS Previous Symbol CUSIP19200510 CIK1200375 Webwww.codexis.com Phone650-421-8100Debt Debt-to-Equity RatioN/A Current Ratio5.62 Quick Ratio5.59Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$68.46 million Price / Sales10.20 Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / Book6.56Profitability EPS (Most Recent Fiscal Year)($0.21) Net Income$-11,940,000.00 Net Margins-20.35% Return on Equity-14.22% Return on Assets-9.74%Miscellaneous Employees132 Outstanding Shares59,127,000Market Cap$698.29 million Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $11.81 +0.13 (+1.11 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CDXS News and Ratings via Email Sign-up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter. Codexis (NASDAQ:CDXS) Frequently Asked Questions How has Codexis' stock been impacted by Coronavirus (COVID-19)? Codexis' stock was trading at $10.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CDXS stock has increased by 16.7% and is now trading at $11.81. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Codexis? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Codexis. When is Codexis' next earnings date? Codexis is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Codexis. How were Codexis' earnings last quarter? Codexis, Inc. (NASDAQ:CDXS) issued its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.02. The biotechnology company earned $14.67 million during the quarter, compared to analysts' expectations of $12.53 million. Codexis had a negative net margin of 20.35% and a negative return on equity of 14.22%. View Codexis' earnings history. What price target have analysts set for CDXS? 3 brokerages have issued 1-year price targets for Codexis' stock. Their forecasts range from $16.00 to $21.00. On average, they anticipate Codexis' stock price to reach $18.50 in the next year. This suggests a possible upside of 56.6% from the stock's current price. View analysts' price targets for Codexis. Who are some of Codexis' key competitors? Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX) and Repligen (RGEN). View all competitors. What other stocks do shareholders of Codexis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Canopy Growth (CGC), Micron Technology (MU), Intellia Therapeutics (NTLA), NVIDIA (NVDA), Opko Health (OPK), Antares Pharma (ATRS) and Corbus Pharmaceuticals (CRBP). Who are Codexis' key executives? Codexis' management team includes the following people: Mr. John J. Nicols, Pres, CEO & Director (Age 55)Mr. Gordon T. B. Sangster, Sr. VP & CFO (Age 66)Dr. James J. Lalonde, Sr. VP of R&D (Age 58)Ms. Laurie Heilmann, Sr. VP of Bus. Devel. & MarketingProf. Gerhard N. Mayr, Special Advisor to the Board (Age 73) What is Codexis' stock symbol? Codexis trades on the NASDAQ under the ticker symbol "CDXS." Who are Codexis' major shareholders? Codexis' stock is owned by many different retail and institutional investors. Top institutional investors include Telemark Asset Management LLC (5.24%), Vanguard Group Inc. (4.83%), Gilder Gagnon Howe & Co. LLC (4.31%), William Blair Investment Management LLC (3.88%), FMR LLC (2.52%) and Goldman Sachs Group Inc. (2.29%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Patrick Y Yang and Thomas R Baruch. View institutional ownership trends for Codexis. Which major investors are selling Codexis stock? CDXS stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., First Light Asset Management LLC, Telemark Asset Management LLC, Gilder Gagnon Howe & Co. LLC, Prescott Group Capital Management L.L.C., William Blair Investment Management LLC, New York State Common Retirement Fund, and Ingalls & Snyder LLC. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, and Thomas R Baruch. View insider buying and selling activity for Codexis. Which major investors are buying Codexis stock? CDXS stock was purchased by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC, Vanguard Group Inc., Cubist Systematic Strategies LLC, Conestoga Capital Advisors LLC, Aigen Investment Management LP, PDT Partners LLC, Assenagon Asset Management S.A., and First Trust Advisors LP. Company insiders that have bought Codexis stock in the last two years include John J Nicols, and Patrick Y Yang. View insider buying and selling activity for Codexis. How do I buy shares of Codexis? Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Codexis' stock price today? One share of CDXS stock can currently be purchased for approximately $11.81. How big of a company is Codexis? Codexis has a market capitalization of $698.29 million and generates $68.46 million in revenue each year. The biotechnology company earns $-11,940,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Codexis employs 132 workers across the globe. What is Codexis' official website? The official website for Codexis is www.codexis.com. How can I contact Codexis? Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected] This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
